December 2015

Safety Related Changes

Eylea (aflibercept) is now also indicated in patients with visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO)

Saizen (somatropin (rmc)) is now also indicated for growth disturbance (growth retardation) in prepubertal children due to chronic renal insufficiency (CRI).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au